Cosby, Richard S.; Herman, Lawrence M.; Talbot, John C.; Mayo, Mary
January 1964
Angiology;Jan1964, Vol. 15 Issue 1, p57
Academic Journal
Focuses on the beneficial effect of long-term anticoagulant therapy on patients suffering from myocardial infarction. Improvement on the quality of life; Reduction on the risks of bleeding episodes; Description on the physical condition of the patients.


Related Articles

  • LONG-TERM ANTICOAGULANT THERAPY. Foley, William T. // Angiology;Jan1964, Vol. 15 Issue 1, p42 

    Focuses on the views of the clinical research teams on the effects of long-term anticoagulant therapy on patients suffering from acute myocardial infarction. Improvement on the quality of life; Reduction on the risks of complications; Decrease on the level of mortality rate.

  • Anticoagulation management of myocardial infarction after deep brain stimulation: a comparison of two cases. Polanski, Witold; Koy, Jan; Juratli, Tareq; Wolz, Martin; Klingelhöfer, Lisa; Fauser, Mareike; Storch, Alexander; Schackert, Gabriele; Sobottka, Stephan // Acta Neurochirurgica;Sep2013, Vol. 155 Issue 9, p1661 

    Deep brain stimulation (DBS) is an established treatment of various diseases, particularly used for idiopathic Parkinson's disease. Frequently, DBS patients are multimorbid and managing them may be challenging, since postoperative complications can become more likely with age. In this article,...

  • Transradial access for primary percutaneous coronary intervention: the next standard of care? Amoroso, Giovanni; Kiemeneij, Ferdinand // Heart;Sep2010, Vol. 96 Issue 17, p1341 

    Objective Primary percutaneous coronary intervention (PPCI) has been acknowledged by the most recent European guidelines to be the preferred treatment for ST elevation myocardial infarction (STEMI). Patients undergoing PPCI are expected to receive a broad spectrum of anticoagulants and...

  • Antithrombotic Agents for Acute Coronary Syndromes. Mukherjee, Debabrata // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 2, p130 

    Current evidence suggests a central role for antithrombotic agents such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the management of acute coronary syndromes (ACS). In patients with acute myocardial infarction, several studies have shown that LMWHs may represent an...

  • Is warfarin a contraindication to thrombolysis in acute ST elevation myocardial infarction? Stanley, A. G.; Fletcher, S.; Tan, A.; Barnett, D. B. // Heart;Aug2006, Vol. 92 Issue 8, p1145 

    The study determines the thrombolysis complication rate among patients prescribed warfarin at the time of admission for a myocardial infarction. Intracranial hemorrhage or gastrointestinal hemorrhage was found to occur more in patients receiving warfarin than in those receiving non-warfarin. The...

  • Koronarni protok i hemoragijske komplikacije posle primene alteplaze i streptokinaze kod bolesnika sa akutnim infarktom miokarda. Kostić, Tomislav; Perišic, Zoran; Milić, Dragan; Apostolović, Svetlana; Martinović, Sonja Šalinger; Božinović, Nenad; Mitov, Vladimir; Vidanović, Miroslav // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Mar2009, Vol. 66 Issue 3, p218 

    Background/Aim. Up-to-date treatment of acute myocardial infarction (AIM) has been based on as early as possible establishment of circulation in ischemic myocardium whether by the use of fibrinolythic therapy and/or urgent coronary intervention which significantly changes the destiny of patients...

  • COMMENTARY: An early invasive strategy reduced death or MI better than a conservative strategy in unstable angina and non-STEMI at advanced age. Bates, Eric R // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p3 

    The article focuses on the study that the TACTICS-TIMI 18 trial that randomized patients with non-ST-elevation acute coronary syndromes to an early invasive or an early conservative management strategy. Older patients had a higher risk for death or myocardial infarction at 6 months and these...

  • Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. Armstrong, Paul W.; Wei-Ching Chang; Wallentin, Lars; Goldstein, Patrick; Granger, Christopher B.; Bogaerts, Kris; Danays, Thierry; Van de Werf, Frans // CMAJ: Canadian Medical Association Journal;5/9/2006, Vol. 174 Issue 10, p1421 

    Background: The optimal antithrombotic therapy to accompany tenecteplase in cases of acute ST-segment elevation myocardial infarction (STEMI) remains unclear. We undertook a prespecified pooled analysis of data from the ASSENT- 3 and ASSENT-3 PLUS trials. Methods: We created a combined database...

  • 2008 - Bivalirudin reduced major bleeding and adverse events in patients with STEMI having PCI. Good, Christopher W.; Berger, Peter B. // ACP Journal Club;9/16/2008, Vol. 149 Issue 3, p9 

    The article presents an answer to the question of how anticoagulation with bivalirudin compares with heparin plus a glycoprotein IIb/IIIa inhibitor in patients suffering from ST-segment elevation myocardial infarction having primary percutaneous coronary intervention.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics